A Phase I, Open-Label Study of Trebananib Combined With Sorafenib or Sunitinib in Patients With Advanced Renal Cell Carcinoma

Autor: Hong, David S., Gordon, Michael S., Samlowski, Wolfram E., Kurzrock, Razelle, Tannir, Nizar, Friedland, David, Mendelson, David S., Vogelzang, Nicholas J., Rasmussen, Erik, Wu, Benjamin M., Bass, Michael B., Zhong, Zhandong D., Friberg, Gregory, Appleman, Leonard J.
Zdroj: In Clinical Genitourinary Cancer June 2014 12(3):167-177
Databáze: ScienceDirect
Externí odkaz: